Assessment of Effectiveness and Safety of Dysport® for the Treatment of Hemifacial Spasm
A Phase III, Multicentre, Randomised, Assessor-blind, Parallel Groups, Reference Drug Controlled Study to Assess the Efficacy and Safety of a Single Administration, by Subcutaneous Injection of Dysport® for the Treatment of Hemifacial Spasm
Sponsor: Ipsen
This PHASE3 trial investigates Hemifacial Spasm and is currently completed. Ipsen leads this study, which shows 8 recorded versions since 2005 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
May 2020 — Jan 2021 [monthly]
Completed PHASE3
-
Aug 2019 — May 2020 [monthly]
Completed PHASE3
▶ Show 3 earlier versions
-
Apr 2019 — Aug 2019 [monthly]
Completed PHASE3
-
Jun 2018 — Apr 2019 [monthly]
Completed PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Dec 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Ipsen
For direct contact, visit the study record on ClinicalTrials.gov .